Avadel Pharmaceuticals PLC
AVDL21.590USD
+0.010+0.05%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.10BMarket Cap
LossP/E TTM
More Details of Avadel Pharmaceuticals PLC Company
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Avadel Pharmaceuticals PLC Info
Ticker SymbolAVDL
Company nameAvadel Pharmaceuticals PLC
IPO dateFeb 21, 2088
CEODivis (Gregory J)
Number of employees188
Security typeOrdinary Share
Fiscal year-endFeb 21
AddressBlock 10-1 Blanchardstown Corporate Park
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code15
Phone35319015201
Websitehttps://www.avadel.com/
Ticker SymbolAVDL
IPO dateFeb 21, 2088
CEODivis (Gregory J)
Company Executives of Avadel Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
100.40K
+14.35%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
100.40K
+14.35%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Mar 3
Currency: USDUpdated: Mon, Mar 3
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
By RegionUSD
Name
Revenue
Proportion
United States
22.33M
100.00%
Ireland
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
7.57%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.98%
Brandes Investment Partners, L.P.
5.55%
Two Seas Capital LP
5.47%
Other
69.17%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
7.57%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.98%
Brandes Investment Partners, L.P.
5.55%
Two Seas Capital LP
5.47%
Other
69.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.38%
Investment Advisor/Hedge Fund
31.72%
Hedge Fund
21.03%
Research Firm
4.62%
Venture Capital
3.46%
Individual Investor
1.06%
Pension Fund
0.46%
Bank and Trust
0.36%
Insurance Company
0.03%
Other
3.89%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
402
92.83M
119.15%
+3.65M
2025Q3
398
82.11M
112.88%
-1.35M
2025Q2
383
83.11M
109.34%
+2.70M
2025Q1
369
80.46M
107.15%
-23.08M
2024Q4
346
82.09M
100.78%
+4.35M
2024Q3
324
77.51M
94.69%
+670.00K
2024Q2
289
76.58M
80.85%
+4.27M
2024Q1
248
72.03M
68.66%
+6.05M
2023Q4
216
57.48M
70.10%
+1.83M
2023Q3
210
56.27M
69.82%
+253.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
11.13M
11.46%
-2.46M
-18.10%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.98M
6.16%
+1.29M
+27.56%
Jun 30, 2025
The Vanguard Group, Inc.
5.54M
5.71%
+1.66M
+42.73%
Jun 30, 2025
Brandes Investment Partners, L.P.
6.49M
6.68%
+820.47K
+14.48%
Jun 30, 2025
Two Seas Capital LP
6.16M
6.34%
+1.21M
+24.43%
Jun 30, 2025
Tontine Asset Management, LLC
5.18M
5.33%
-950.54K
-15.51%
Jun 30, 2025
Polar Capital LLP
4.00M
4.12%
-356.63K
-8.19%
Jun 30, 2025
Vivo Capital, LLC
2.68M
2.76%
--
--
Jun 30, 2025
State Street Investment Management (US)
2.07M
2.13%
+412.10K
+24.84%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Innovator IBD 50 Fund ETF
3.77%
Invesco Pharmaceuticals ETF
3.4%
iShares Neuroscience and Healthcare ETF
3.21%
ProShares Merger ETF
2.82%
State Street SPDR S&P Pharmaceuticals ETF
2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.39%
AltShares Event-Driven ETF
1.21%
First Trust Small Cap Growth AlphaDEX Fund
1.02%
iShares U.S. Pharmaceuticals ETF
0.68%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.4%
View more
Innovator IBD 50 Fund ETF
Proportion3.77%
Invesco Pharmaceuticals ETF
Proportion3.4%
iShares Neuroscience and Healthcare ETF
Proportion3.21%
ProShares Merger ETF
Proportion2.82%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.39%
AltShares Event-Driven ETF
Proportion1.21%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.02%
iShares U.S. Pharmaceuticals ETF
Proportion0.68%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.4%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Avadel Pharmaceuticals PLC?
The top five shareholders of Avadel Pharmaceuticals PLC are:
Janus Henderson Investors holds 11.13M shares, accounting for 11.46% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.98M shares, accounting for 6.16% of the total shares.
The Vanguard Group, Inc. holds 5.54M shares, accounting for 5.71% of the total shares.
Brandes Investment Partners, L.P. holds 6.49M shares, accounting for 6.68% of the total shares.
Two Seas Capital LP holds 6.16M shares, accounting for 6.34% of the total shares.
Janus Henderson Investors holds 11.13M shares, accounting for 11.46% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.98M shares, accounting for 6.16% of the total shares.
The Vanguard Group, Inc. holds 5.54M shares, accounting for 5.71% of the total shares.
Brandes Investment Partners, L.P. holds 6.49M shares, accounting for 6.68% of the total shares.
Two Seas Capital LP holds 6.16M shares, accounting for 6.34% of the total shares.
What are the top three shareholder types of Avadel Pharmaceuticals PLC?
The top three shareholder types of Avadel Pharmaceuticals PLC are:
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Avadel Pharmaceuticals PLC (AVDL)?
As of 2025Q4, 402 institutions hold shares of Avadel Pharmaceuticals PLC, with a combined market value of approximately 92.83M, accounting for 119.15% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 6.27%.
What is the biggest source of revenue for Avadel Pharmaceuticals PLC?
In FY2020, the Vazculep business generated the highest revenue for Avadel Pharmaceuticals PLC, amounting to 10.43M and accounting for 46.70% of total revenue.
